# Shandong Boan Biotechnology Co., Ltd.
# 山东博安生物技术股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6955)**

## VOLUNTARY ANNOUNCEMENT

## BOYOUJING® (AFLIBERCEPT INTRAVITREOUS INJECTION) APPROVED FOR MARKETING IN CHINA

The board of directors (the "**Board**") of Shandong Boan Biotechnology Co., Ltd. (the "**Company**") announces that China's National Medical Products Administration has granted marketing approval for its aflibercept intravitreous injection, Boyoujing®, which is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) in adults. The Company will work with Ocumension Therapeutics ("**Ocumension**"), a leading Chinese platform for ophthalmic drugs, to commercialize this product in the Chinese Mainland.

Boyoujing® is a biosimilar to EYLEA®. Its active ingredient is aflibercept, a humanized fusion protein binding with vascular endothelial growth factors (VEGF-A and VEGF-B) and placental growth factor (PlGF) to reach more targets than anti-VEGF monoclonal antibodies. As a first-line treatment for nAMD, DME, and other retinal diseases, aflibercept sustainably inhibits intraocular VEGFs to effectively improve visual acuity with a durable efficacy and a favorable overall safety and tolerability profile.

Globally, EYLEA® has been approved for various ophthalmic indications, including nAMD, DME, macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR), visual impairment due to myopic choroidal neovascularization (mCNV), and retinopathy of prematurity (ROP). In China, EYLEA® has been approved for the treatment of nAMD and DME.

The development of Boyoujing® adhered to regulatory guidelines for biosimilars, and its similarity to EYLEA® was established through a series of analytical, non-clinical, and clinical studies. The two products showed a high degree of similarity in quality, efficacy, safety, and immunogenicity, with no clinically meaningful differences. In a Phase I clinical trial, Boyoujing® and the reference product (the originator drug) demonstrated comparable safety and tolerability. In a Phase III clinical trial, both Boyoujing® and the reference product produced clinically meaningful improvements in best-corrected visual acuity (BCVA) from baseline, as measured by the ETDRS chart at Weeks 4, 8, 12, 16, 20, and 24. Boyoujing® demonstrated high comparability to the reference product, with rapid onset of action and sustained efficacy, meeting all clinical endpoints.

Retinal diseases, including nAMD and DME, are serious eye conditions that significantly compromise patients' health and quality of life. DME is a major complication of diabetes and one of the leading causes for vision loss among diabetic patients, affecting approximately 5.2% of the 148 million individuals aged 20 to 79 with diabetes in China. AMD is another leading cause for visual impairments and blindness in the elderly, affecting 20.2% of individuals over 70 years of age in China. Although nAMD accounts for only 10–20% of all AMD cases, it is responsible for approximately 90% of the AMD-related blindness.

A huge number of patients have led to the rapid growth of anti-angiogenic ophthalmic therapies in China. According to IQVIA, the size of the market for such therapies increased from RMB1.27 billion in 2018 to RMB4.99 billion in 2024, with a compound annual growth rate (CAGR) of 25.6%.

To accelerate patient access to Boyoujing®, the Company entered into an agreement with Ocumension in 2020 to jointly conduct a Phase III clinical trial of Boyoujing® in China and granted Ocumension the exclusive right to promote and commercialize the product in the Chinese Mainland. As a leading platform for ophthalmic products in China, Ocumension is dedicated to building integrated capabilities across the full lifecycle of ophthalmic medicines, from research and development and manufacturing to commercialization. With a portfolio of 43 ophthalmic drugs under development and/or on the market, a sales and marketing team of several hundred professionals and a well-established commercial network reaching over 20,000 hospitals nationwide, Ocumension is well positioned to support a successful launch. By leveraging each other's strengths and adopting an efficient collaboration model, the parties aim to ensure Boyoujing® is successfully launched, accessible and affordable to patients, and a driver of the Company's long-term growth.

Besides the Chinese market, the Company is also actively driving the development of Boyoujing® abroad. The Company has granted Kexing Risedo Pharm Co., Ltd., which is a wholly-owned subsidiary of Kexing Biopharm, the exclusive right to market and distribute Boyoujing® in specified markets, which include all countries and regions other than the Chinese Mainland, the EU, the UK, the US, and Japan.

By Order of the Board
**Shandong Boan Biotechnology Co., Ltd.**
**Jiang Hua**
*Chairlady, Chief Executive Officer and Executive Director*

Yantai, the People's Republic of China, 26 November 2025

*As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua, Dr. Dou Changlin and Mr. Wang Shenghan; the non-executive directors of the Company are Mr. Liu Yuanchong, Ms. Li Li and Mr. Li Shixu; and the independent non-executive directors of the Company are Professor Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.*